Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2020 October;72(5) > Minerva Urologica e Nefrologica 2020 October;72(5):555-62

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   Free accessfree

Minerva Urologica e Nefrologica 2020 October;72(5):555-62

DOI: 10.23736/S0393-2249.20.03782-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Conservative management of urinary incontinence following robot-assisted radical prostatectomy

Michele MARCHIONI 1, 2, 3 , Giulia PRIMICERI 1, Pietro CASTELLAN 2, Luigi SCHIPS 1, 2, Guglielmo MANTICA 3, 4, Christopher CHAPPLE 5, Rocco PAPALIA 6, Francesco PORPIGLIA 7, Roberto M. SCARPA 6, Francesco ESPERTO 3, 6

1 Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, G. d’Annunzio University, Chieti, Italy; 2 Department of Urology, ASL Abruzzo 2, Chieti, Italy; 3 European Association of Urology - European Society of Residents in Urology (EAU-ESRU); 4 Department of Urology, San Martino Polyclinic Hospital, University of Genoa, Genoa, Italy; 5 Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK; 6 Department of Urology, Campus Bio-Medico University, Rome, Italy; 7 Division of Urology, Department of Oncology, School of Medicine, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy



INTRODUCTION: Robotic assisted radical prostatectomy (RARP) is getting more and more popular becoming the most common radical prostatectomy technique. Unfortunately, a not negligible proportion of patients in whom RARP is performed experience urinary incontinence. We aimed to systematically review the current literature evidence on urinary incontinence conservative treatment after RARP.
EDIDENCE AQUISITION: A systematic literature review search using PubMed (Medline), Scopus, and Web of Science databases was performed in December 2019. PRISMA guidelines have been adopted. Population consisted of patients with urinary incontinence after RARP (P), conservative intervention was considered of interest (I). No comparator was considered mandatory (C). Outcomes of interest were the recovery of continence and quality of life (O).
EVIDEDENCE SYNTHESIS: Six studies were included. Four of them investigated the use of pelvic floor muscle training (PFMT). PFMT improved pelvic muscle strength. Continence recovery was faster when guided PFMT was adopted. Moreover, two studies tested the effect of solifenacin on urinary incontinence. One of them, a randomized clinical trial, failed to show shorter time to continence in solifenacin group compared to placebo.
CONCLUSIONS: The use of pads is associated with a detrimental effect on quality of life thus active treatments for UI post-RARP are warranted. PFMT has the main advantage to shorten the time for recovery. The use of solifenacin seems to not offer striking advantages in UI following RARP. Future studies should focus on testing the efficacy of these treatments when used after robotic vs. open radical prostatectomy.


KEY WORDS: Robotics; Prostatectomy; Prostatic neoplasms; Urinary incontinence

top of page